924727476	924727476	CD	B-NP	O
|	|	NN	I-NP	O
CG	CG	NN	I-NP	O
|	|	NN	I-NP	O
42816438	42816438	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
7011259	7011259	CD	B-NP	O
|	|	CC	I-NP	O
8/6/2006	8/6/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
RIGHT	RIGHT	NNP	I-NP	I-protein
CHRONIC	CHRONIC	NNP	I-NP	I-protein
LEG	LEG	NNP	I-NP	I-protein
ULCER	ULCER	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
3/6/2006	3/6/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/16/2006	1/16/2006	CD	B-NP	O
Date	Date	NN	I-NP	O
of	of	IN	B-PP	O
Admission	Admission	NN	B-NP	O
:	:	:	O	O
3/6/2006	3/6/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
DEROCHER	DEROCHER	NN	B-NP	O
,	,	,	O	O
SHAUN	SHAUN	NNP	B-NP	O
ANTONIO	ANTONIO	NNP	I-NP	O
MD	MD	NNP	I-NP	O
ADDENDUM	ADDENDUM	NNP	I-NP	O
:	:	:	O	O
ADMISSION	ADMISSION	NN	B-NP	O
TO	TO	TO	B-PP	O
THE	THE	DT	B-NP	O
ICU	ICU	NN	I-NP	B-DNA
:	:	:	O	I-DNA
2/8/06	2/8/06	CD	B-NP	I-DNA
.	.	.	O	O

This	This	DT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
and	and	CC	I-NP	O
plan	plan	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
the	the	DT	B-NP	O
discharge	discharge	NN	I-NP	O
medications	medication	NNS	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Lower	Low	JJR	B-NP	O
extremity	extremity	NN	I-NP	O
wounds	wound	NNS	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
several	several	JJ	B-NP	O
left	leave	VBD	B-VP	O
lower	low	JJR	B-NP	O
extremity	extremity	NN	I-NP	O
wounds	wound	NNS	I-NP	O
which	which	WDT	B-NP	O
by	by	IN	B-PP	O
report	report	NN	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
chronic	chronic	JJ	B-ADJP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
deeper	deep	JJR	I-NP	O
acute	acute	JJ	I-NP	O
onset	onset	NN	I-NP	O
right	right	RB	B-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
wound	wound	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
ulcerated	ulcerate	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
level	level	NN	I-NP	O
of	of	IN	B-PP	O
muscle	muscle	NN	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
wound	wound	NN	I-NP	O
had	have	VBD	B-VP	O
occurred	occur	VBN	I-VP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
hematoma	hematoma	NN	I-NP	O
after	after	IN	B-PP	O
incision	incision	NN	B-NP	O
and	and	CC	I-NP	O
drainage	drainage	NN	I-NP	O
by	by	IN	B-PP	O
Surgical	Surgical	NNP	B-NP	O
Service	Service	NNP	I-NP	O
one	one	CD	B-NP	O
to	to	TO	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
obvious	obvious	JJ	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
infection	infection	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
certainly	certainly	RB	B-ADJP	O
possible	possible	JJ	I-ADJP	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
soft	soft	JJ	I-NP	O
tissue	tissue	NN	I-NP	O
surrounding	surround	VBG	B-VP	O
that	that	DT	B-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
some	some	DT	B-NP	O
thought	thought	NN	I-NP	O
of	of	IN	B-PP	O
whether	whether	IN	B-SBAR	O
that	that	DT	B-NP	O
could	could	MD	B-VP	O
be	be	VB	I-VP	O
osteomyelitis	osteomyelitis	NN	B-NP	O
underlying	underlie	VBG	B-VP	O
the	the	DT	B-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
tibial	tibial	JJ	B-NP	O
and	and	CC	I-NP	O
fibula	fibula	NN	I-NP	O
films	film	NNS	I-NP	O
which	which	WDT	B-NP	O
at	at	IN	B-PP	O
first	first	JJ	B-ADJP	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
some	some	DT	B-NP	O
consideration	consideration	NN	I-NP	O
of	of	IN	B-PP	O
whether	whether	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
abnormality	abnormality	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
bone	bone	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
further	further	JJ	B-NP	O
consideration	consideration	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
not	not	RB	O	O
the	the	DT	B-NP	O
case	case	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
to	to	TO	B-VP	O
evaluate	evaluate	VB	I-VP	O
more	more	RBR	B-ADVP	O
specifically	specifically	RB	I-ADVP	O
a	a	DT	B-NP	O
bone	bone	NN	I-NP	O
scan	scan	NN	I-NP	O
was	be	VBD	B-VP	O
performed	perform	VBN	I-VP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
uptake	uptake	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
that	that	DT	B-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
some	some	DT	B-NP	O
mild	mild	JJ	I-NP	O
uptake	uptake	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
Achilles	Achilles	NNP	I-NP	O
tendon	tendon	NN	I-NP	O
calcaneal	calcaneal	JJ	I-NP	O
insertion	insertion	NN	I-NP	O
and	and	CC	O	O
marked	marked	JJ	B-NP	O
uptake	uptake	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
T9	T9	NN	I-NP	O
thoracic	thoracic	JJ	I-NP	O
9th	9th	JJ	I-NP	O
vertebrae	vertebra	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
CAT	CAT	NN	I-NP	B-protein
scan	scan	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
spine	spine	NN	I-NP	O
was	be	VBD	B-VP	O
performed	perform	VBN	I-VP	O
which	which	WDT	B-NP	O
revealed	reveal	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
infection	infection	NN	B-NP	O
or	or	CC	I-NP	O
neoplasm	neoplasm	NN	I-NP	O
but	but	CC	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
osteopenia	osteopenia	NN	B-NP	O
and	and	CC	O	O
possibly	possibly	RB	B-ADVP	O
a	a	DT	B-NP	O
microfracture	microfracture	NN	I-NP	O
but	but	CC	O	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
real	real	JJ	B-NP	O
compression	compression	NN	I-NP	O
fracture	fracture	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
and	and	CC	I-VP	O
examined	examine	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Vascular	Vascular	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Consult	Consult	NNP	I-NP	O
Service	Service	NNP	I-NP	O
and	and	CC	O	O
Dr.	Dr.	NNP	B-NP	O
Smallidge	Smallidge	NNP	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
vascular	vascular	JJ	I-NP	O
surgeon	surgeon	NN	I-NP	O
.	.	.	O	O

Their	Their	PRP$	B-NP	O
recommendation	recommendation	NN	I-NP	O
in	in	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
wound	wound	NN	B-NP	O
dressing	dressing	NN	I-NP	O
was	be	VBD	B-VP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
wet-to-dry	wet-to-dry	JJ	B-NP	O
dressing	dress	VBG	I-NP	O
changes	change	NNS	I-NP	O
with	with	IN	B-PP	O
4	4	CD	B-NP	O
x	x	NN	I-NP	O
8	8	CD	B-NP	O
gauze	gauze	NN	I-NP	O
sponges	sponge	NNS	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Goolden	Goolden	NNP	I-NP	O
in	in	IN	B-PP	O
mid	mid	JJ	B-NP	O
9/6	9/6	CD	I-NP	O
.	.	.	O	O

Please	Please	NNP	B-NP	O
call	call	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Usman	Usman	NNP	I-NP	O
's	's	POS	B-NP	O
office	office	NN	I-NP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
recommendation	recommendation	NN	I-NP	O
for	for	IN	B-PP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
wet-to-dry	wet-to-dry	JJ	I-NP	O
dressings	dressing	NNS	I-NP	O
without	without	IN	B-PP	O
additional	additional	JJ	B-NP	O
ointments	ointment	NNS	I-NP	O
or	or	CC	I-NP	O
treatments	treatment	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
wound	wound	NN	B-NP	O
care	care	NN	I-NP	O
service	service	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
small	small	JJ	B-NP	B-protein
necrotic	necrotic	JJ	I-NP	I-protein
regions	region	NNS	I-NP	I-protein
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
heels	heel	NNS	I-NP	O
.	.	.	O	O

These	These	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Panafil	Panafil	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
sacral	sacral	JJ	I-NP	O
decubitus	decubitus	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Plastic	Plastic	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
,	,	,	O	O
they	they	PRP	B-NP	O
debrided	debride	VBD	B-VP	O
the	the	DT	B-NP	O
wound	wound	NN	I-NP	O
twice	twice	RB	B-ADVP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
minimal	minimal	JJ	B-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
superficial	superficial	JJ	B-NP	O
necrotic	necrotic	JJ	I-NP	O
tissue	tissue	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
excised	excise	VBN	I-VP	O
.	.	.	O	O

Their	Their	PRP$	B-NP	O
recommendations	recommendation	NNS	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
care	care	NN	I-NP	O
were	be	VBD	B-VP	O
to	to	TO	I-VP	O
apply	apply	VB	I-VP	O
one-quarter	one-quarter	JJ	B-NP	O
strength	strength	NN	I-NP	O
Dakin	Dakin	NNP	B-NP	O
's	's	POS	B-NP	O
solution	solution	NN	I-NP	O
soaked	soak	VBD	B-VP	O
wet-to-dry	wet-to-dry	JJ	B-NP	O
dressings	dressing	NNS	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
changed	change	VBN	I-VP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
for	for	IN	B-PP	O
48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
that	that	WDT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
for	for	IN	B-PP	O
36	36	CD	B-NP	O
hours	hour	NNS	I-NP	O
from	from	IN	B-PP	O
discharge	discharge	NN	B-NP	O
and	and	CC	O	O
then	then	RB	O	O
this	this	DT	B-NP	O
treatment	treatment	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
standard	standard	JJ	B-NP	O
wet-to-dry	wet-to-dry	JJ	I-NP	O
dressings	dressing	NNS	I-NP	O
twice	twice	RB	B-ADJP	O
daily	daily	RB	I-ADJP	O
to	to	TO	B-PP	O
that	that	DT	B-NP	O
sacral	sacral	JJ	I-NP	O
decubitus	decubitus	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
recommend	recommend	VBP	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
be	be	VB	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
air	air	NN	I-NP	O
mattress	mattress	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
turns	turn	NNS	B-NP	O
at	at	IN	B-ADVP	O
least	least	JJS	I-ADVP	O
every	every	DT	B-NP	O
2	2	CD	I-NP	O
hours	hour	NNS	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
also	also	RB	B-ADVP	O
recommend	recommend	VBP	B-VP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
be	be	VB	B-VP	O
kept	keep	VBN	I-VP	O
off	off	IN	B-PP	O
the	the	DT	B-NP	O
sacrum	sacrum	NN	I-NP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
nutrition	nutrition	NN	I-NP	O
be	be	VB	B-VP	O
optimized	optimize	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
multivitamin	multivitamin	NN	I-NP	O
,	,	,	O	O
continued	continue	VBN	B-VP	O
on	on	IN	B-PP	O
calcium	calcium	NN	B-NP	O
,	,	,	O	O
started	start	VBN	B-VP	O
on	on	IN	B-PP	O
zinc	zinc	NN	B-NP	O
,	,	,	O	O
vitamin	vitamin	NN	B-NP	O
C	C	NN	I-NP	O
supplements	supplement	NNS	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Roscoe	Roscoe	NNP	I-NP	O
Szymonik	Szymonik	NNP	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
scheduled	schedule	VBN	I-VP	O
by	by	IN	B-PP	O
calling	call	VBG	B-VP	O
390-948-8630	390-948-8630	CD	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
low-grade	low-grade	JJ	I-NP	O
temperature	temperature	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
unclear	unclear	JJ	B-ADJP	O
whether	whether	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
primary	primary	JJ	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	O	O
what	what	WP	B-NP	O
the	the	DT	B-NP	O
source	source	NN	I-NP	O
of	of	IN	B-PP	O
that	that	DT	B-NP	O
infection	infection	NN	I-NP	O
was	be	VBD	B-VP	O
.	.	.	O	O

Cultures	Culture	NNS	B-NP	O
were	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
from	from	IN	B-PP	O
blood	blood	NN	B-NP	O
,	,	,	O	O
urine	urine	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
sputum	sputum	NN	B-NP	O
.	.	.	O	O

All	All	DT	B-NP	O
blood	blood	NN	I-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Urine	Urine	NN	B-NP	O
culture	culture	NN	I-NP	O
grew	grow	VBD	B-VP	O
extended	extend	VBN	B-NP	O
spectrum	spectrum	NN	I-NP	O
beta-lactamase	beta-lactamase	NN	I-NP	O
resistant	resistant	JJ	I-NP	O
Klebsiella	Klebsiella	NN	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
intermediate	intermediate	JJ	B-ADJP	O
to	to	TO	B-PP	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O
and	and	CC	O	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
.	.	.	O	O

Because	Because	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
so	so	RB	B-NP	O
little	little	JJ	I-NP	O
urine	urine	NN	I-NP	O
output	output	NN	I-NP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
unclear	unclear	JJ	B-ADJP	O
whether	whether	IN	B-SBAR	O
at	at	IN	B-PP	O
first	first	RB	B-NP	O
this	this	DT	I-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
colonizer	colonizer	NN	I-NP	O
or	or	CC	O	O
an	an	DT	B-NP	O
actual	actual	JJ	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
consultation	consultation	NN	I-NP	O
was	be	VBD	B-VP	O
requested	request	VBN	I-VP	O
.	.	.	O	O

Their	Their	PRP$	B-NP	O
recommendations	recommendation	NNS	I-NP	O
were	be	VBD	B-VP	O
to	to	TO	I-VP	O
start	start	VB	I-VP	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
when	when	WRB	B-ADVP	O
the	the	DT	B-NP	O
final	final	JJ	I-NP	O
susceptibilities	susceptibility	NNS	I-NP	O
came	come	VBD	B-VP	O
back	back	RB	B-ADVP	O
and	and	CC	O	O
they	they	PRP	B-NP	O
continued	continue	VBD	B-VP	O
that	that	IN	B-SBAR	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
two-week	two-week	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
48h	48h	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
course	course	NN	I-NP	O
will	will	MD	B-VP	O
finish	finish	VB	I-VP	O
on	on	IN	B-PP	O
9/4/06	9/4/06	CD	B-NP	O
.	.	.	O	O

Sputum	Sputum	NN	B-NP	O
cultures	culture	NNS	I-NP	O
grew	grow	VBD	B-VP	O
multidrug	multidrug	JJ	B-NP	O
resistant	resistant	JJ	I-NP	O
Pseudomonas	Pseudomonas	NN	I-NP	O
aeruginosa	aeruginosa	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
few	few	JJ	I-NP	O
Acinetobacter	Acinetobacter	NN	I-NP	O
which	which	WDT	B-NP	O
were	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
resistant	resistant	JJ	B-ADJP	O
to	to	TO	B-PP	O
many	many	JJ	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
close	close	JJ	B-NP	O
consultation	consultation	NN	I-NP	O
with	with	IN	B-PP	O
Infectious	Infectious	NNP	B-NP	O
Disease	Disease	NNP	I-NP	O
Consultation	Consultation	NNP	I-NP	O
Service	Service	NNP	I-NP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
that	that	IN	B-SBAR	O
these	these	DT	B-NP	O
were	be	VBD	B-VP	O
most	most	RBS	B-NP	O
likely	likely	JJ	I-NP	O
colonizers	colonizer	NNS	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
an	an	DT	B-NP	O
acute	acute	JJ	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
or	or	CC	I-NP	O
tracheobronchitis	tracheobronchitis	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
colonization	colonization	NN	I-NP	O
with	with	IN	B-PP	O
Acinetobacter	Acinetobacter	NN	B-NP	O
and	and	CC	I-NP	O
Pseudomonas	Pseudomonas	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
multiple	multiple	JJ	B-NP	O
other	other	JJ	I-NP	O
multiple	multiple	JJ	I-NP	O
drug	drug	NN	I-NP	O
resistant	resistant	JJ	I-NP	O
organisms	organism	NNS	I-NP	O
that	that	WDT	B-NP	O
grew	grow	VBD	B-VP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	B-cell_line
sputum	sputum	NN	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
at	at	IN	B-PP	O
other	other	JJ	B-NP	O
institutions	institution	NNS	I-NP	O
and	and	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
that	that	IN	B-SBAR	O
unless	unless	IN	B-SBAR	O
she	she	PRP	B-NP	O
demonstrated	demonstrate	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
clinical	clinical	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
infection	infection	NN	I-NP	O
these	these	DT	B-NP	O
should	should	MD	B-VP	O
not	not	RB	I-VP	O
be	be	VB	I-VP	O
treated	treat	VBN	I-VP	O
.	.	.	O	O

Overall	Overall	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
hemodynamic	hemodynamic	JJ	I-NP	O
status	status	NN	I-NP	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

Several	Several	JJ	B-NP	O
days	day	NNS	I-NP	O
into	into	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
one	one	CD	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
low	low	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
initially	initially	RB	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
fluids	fluid	NNS	I-NP	O
and	and	CC	B-NP	O
then	then	RB	I-NP	O
norepinephrine	norepinephrine	NN	B-NP	O
infusion	infusion	NN	I-NP	O
for	for	IN	B-PP	O
short	short	JJ	B-NP	O
period	period	NN	I-NP	O
of	of	IN	B-PP	O
time	time	NN	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
repeat	repeat	NN	B-NP	O
cuff	cuff	NN	I-NP	O
pressure	pressure	NN	I-NP	O
manually	manually	RB	B-ADVP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
revealed	reveal	VBN	I-VP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
actually	actually	RB	B-ADVP	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
dysfunction	dysfunction	NN	B-NP	O
possibly	possibly	RB	B-ADVP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
her	her	PRP$	B-NP	O
obesity	obesity	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
automatic	automatic	JJ	I-NP	O
cuff	cuff	NN	I-NP	O
,	,	,	O	O
therefore	therefore	RB	B-ADVP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
low	low	JJ	I-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
spurious	spurious	JJ	B-ADJP	O
and	and	CC	O	O
probably	probably	RB	B-ADVP	O
an	an	DT	B-NP	O
artifact	artifact	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
cuff	cuff	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
being	be	VBG	I-VP	O
used	use	VBN	I-VP	O
.	.	.	O	O

So	So	RB	O	O
in	in	IN	B-PP	O
conclusion	conclusion	NN	B-NP	O
the	the	DT	B-NP	O
only	only	JJ	I-NP	O
medication	medication	NN	I-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
levofloxacin	levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
48h	48h	NN	I-NP	O
.	.	.	O	O

through	through	IN	B-PP	O
9/4/06	9/4/06	CD	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
Toprol	Toprol	NNP	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	O
two	two	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
ranged	range	VBD	B-VP	O
from	from	IN	B-PP	O
120s-130s	120s-130s	CD	B-NP	O
when	when	WRB	B-ADVP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
first	first	RB	I-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
50s-60s	50s-60	NNS	B-NP	B-DNA
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
readdressed	readdresse	VBN	I-VP	O
regularly	regularly	RB	B-ADVP	O
in	in	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
need	need	NN	I-NP	O
for	for	IN	B-PP	O
rate	rate	NN	B-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
that	that	DT	B-NP	O
low	low	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
beta-blocker	beta-blocker	NN	B-NP	O
.	.	.	O	O

Otherwise	Otherwise	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
INR	INR	NN	I-NP	B-protein
of	of	IN	B-PP	O
2-3	2-3	NN	B-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
St.	St.	NNP	I-NP	O
Jude	Jude	NNP	I-NP	O
's	's	POS	B-NP	O
aortic	aortic	JJ	I-NP	O
valve	valve	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
actually	actually	RB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
couple	couple	NN	I-NP	O
of	of	IN	B-PP	O
days	day	NNS	B-NP	O
in	in	IN	B-PP	O
anticipation	anticipation	NN	B-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
possible	possible	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
heparin	heparin	NN	B-NP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
bridge	bridge	NN	I-NP	O
for	for	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
meantime	meantime	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
heparin	heparin	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
PTT	PTT	NN	I-NP	O
of	of	IN	B-PP	O
50-70	50-70	CD	B-NP	O
until	until	IN	B-PP	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
is	be	VBZ	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
at	at	IN	B-PP	O
2-3	2-3	NN	B-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
rechecked	rechecke	VBN	I-VP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
sure	sure	JJ	B-ADJP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
remains	remain	VBZ	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
care	care	NN	I-NP	O
was	be	VBD	B-VP	O
discussed	discuss	VBN	I-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Sean	Sean	NNP	I-NP	O
Mesa	Mesa	NNP	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
type	type	NN	B-NP	O
2	2	CD	I-NP	O
diabetes	diabete	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
diabetes	diabetes	NN	I-NP	O
was	be	VBD	B-VP	O
controlled	control	VBN	I-VP	O
with	with	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
NPH	NPH	NN	I-NP	I-protein
35	35	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneous	subcutaneous	JJ	B-ADJP	O
every	every	DT	B-NP	O
morning	morning	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
insulin	insulin	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
every	every	DT	B-NP	O
6	6	CD	I-NP	O
hours	hour	NNS	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
and	and	CC	O	O
fingersticks	fingerstick	NNS	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
done	do	VBN	I-VP	O
every	every	DT	B-NP	O
6	6	CD	I-NP	O
hours	hour	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
hypothyroidism	hypothyroidism	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
thyroid	thyroid	NN	I-NP	O
stimulating	stimulate	VBG	B-VP	O
hormone	hormone	NN	B-NP	O
level	level	NN	I-NP	O
was	be	VBD	B-VP	O
checked	check	VBN	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
elevated	elevate	VBN	I-VP	O
at	at	IN	B-PP	O
14.5	14.5	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
thyroid	thyroid	JJ	I-NP	O
replacement	replacement	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
increased	increase	VBN	I-VP	O
from	from	IN	B-PP	O
75	75	CD	B-NP	O
mcg	mcg	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
to	to	TO	B-PP	O
88	88	CD	B-NP	O
mcg	mcg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
thyroid	thyroid	NN	I-NP	O
stimulating	stimulate	VBG	B-VP	O
hormone	hormone	NN	B-NP	O
level	level	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
again	again	RB	B-ADVP	O
in	in	IN	B-PP	O
four	four	CD	B-NP	O
to	to	TO	I-NP	O
six	six	CD	I-NP	O
weeks	week	NNS	I-NP	O
and	and	CC	I-NP	O
dose	dose	NN	I-NP	O
adjustment	adjustment	NN	I-NP	O
accordingly	accordingly	RB	B-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
mechanical	mechanical	JJ	I-NP	O
ventilation	ventilation	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
were	be	VBD	B-VP	O
attempts	attempt	NNS	B-NP	O
at	at	IN	B-PP	O
lower	low	JJR	B-NP	O
pressure	pressure	NN	I-NP	O
support	support	NN	I-NP	O
and	and	CC	O	O
even	even	RB	B-NP	O
spontaneously	spontaneously	RB	I-NP	O
breathing	breathing	JJ	I-NP	O
trials	trial	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
tolerate	tolerate	VB	I-VP	O
these	these	DT	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
long	long	JJ	I-NP	O
period	period	NN	I-NP	O
of	of	IN	B-PP	O
time	time	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
it	it	PRP	B-NP	O
does	do	VBZ	B-VP	O
seem	seem	VB	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
improved	improve	VBN	I-VP	O
to	to	TO	B-PP	O
some	some	DT	B-NP	O
degree	degree	NN	I-NP	O
in	in	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
ventilatory	ventilatory	JJ	I-NP	O
mechanics	mechanic	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
on	on	IN	B-PP	O
pressure	pressure	NN	B-NP	O
support	support	NN	I-NP	O
ventilation	ventilation	NN	I-NP	O
at	at	IN	B-PP	O
15	15	CD	B-NP	O
of	of	IN	B-PP	O
pressure	pressure	NN	B-NP	O
support	support	NN	I-NP	O
and	and	CC	O	O
5	5	CD	B-NP	O
of	of	IN	B-PP	O
positive	positive	JJ	B-NP	O
end	end	NN	I-NP	O
expiratory	expiratory	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
FIO2	FIO2	NN	I-NP	B-protein
of	of	IN	B-PP	O
0.4	0.4	CD	B-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
believe	believe	VBP	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
could	could	MD	B-VP	O
probably	probably	RB	I-VP	O
be	be	VB	I-VP	O
weaned	wean	VBN	I-VP	O
slowly	slowly	RB	B-ADVP	O
to	to	TO	B-PP	O
significantly	significantly	RB	B-NP	O
decreased	decrease	VBN	I-NP	O
pressure	pressure	NN	I-NP	O
support	support	NN	I-NP	O
and	and	CC	O	O
I	I	PRP	B-NP	O
believe	believe	VBP	B-VP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
able	able	JJ	B-ADJP	O
at	at	IN	B-PP	O
some	some	DT	B-NP	O
point	point	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
taken	take	VBN	I-VP	O
off	off	RP	B-PRT	O
the	the	DT	B-NP	O
ventilator	ventilator	NN	I-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
certainly	certainly	RB	B-ADVP	O
not	not	RB	O	O
certain	certain	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatments	treatment	NNS	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Nutrition	Nutrition	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
full	full	JJ	B-NP	O
strength	strength	NN	I-NP	O
Nepro	Nepro	NN	I-NP	O
at	at	IN	B-PP	O
50	50	CD	B-NP	O
cc	cc	NN	I-NP	O
per	per	IN	B-PP	O
hour	hour	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
getting	get	VBG	I-VP	O
vitamin	vitamin	NN	B-NP	O
C	C	NN	I-NP	O
supplementation	supplementation	NN	I-NP	O
,	,	,	O	O
ascorbic	ascorbic	JJ	B-NP	O
acid	acid	NN	I-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	O
two	two	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
Nephrocaps	Nephrocap	NNS	B-NP	O
,	,	,	O	O
zinc	zinc	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
220	220	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	O
daily	daily	RB	B-ADVP	O
and	and	CC	O	O
these	these	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
as	as	IN	B-SBAR	O
indicated	indicate	VBN	B-VP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
wound	wound	NN	B-NP	O
healing	healing	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Psychiatric	Psychiatric	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
fluoxetine	fluoxetine	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
daily	daily	JJ	I-NP	O
and	and	CC	O	O
on	on	IN	B-PP	O
Zyprexa	Zyprexa	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
Throughout	Throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
esomeprazole	esomeprazole	NN	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
and	and	CC	O	O
for	for	IN	B-PP	O
deep	deep	JJ	B-NP	O
venous	venous	JJ	I-NP	O
thrombosis	thrombosis	NN	I-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
remained	remain	VBD	B-VP	O
above	above	IN	B-PP	O
1.4	1.4	CD	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
PTT	PTT	NN	I-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
on	on	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
.	.	.	O	O

Intravenous	Intravenous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
with	with	IN	B-PP	O
PTT	PTT	NN	B-NP	B-protein
checks	check	NNS	I-NP	I-protein
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
every	every	DT	B-NP	O
6	6	CD	I-NP	O
hours	hour	NNS	I-NP	O
unit	unit	NN	I-NP	O
they	they	PRP	B-NP	O
were	be	VBD	B-VP	O
fairly	fairly	RB	B-ADJP	O
stable	stable	JJ	I-ADJP	O
between	between	IN	B-PP	O
50	50	CD	B-NP	O
and	and	CC	I-NP	O
70	70	CD	I-NP	O
and	and	CC	O	O
that	that	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
at	at	IN	B-ADVP	O
least	least	JJS	I-ADVP	O
daily	daily	RB	B-ADVP	O
until	until	IN	B-PP	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
is	be	VBZ	B-VP	O
stably	stably	RB	B-ADJP	O
therapeutic	therapeutic	JJ	I-ADJP	O
.	.	.	O	O

It	It	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
very	very	RB	B-ADJP	O
important	important	JJ	I-ADJP	O
to	to	TO	B-VP	O
monitor	monitor	VB	I-VP	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
carefully	carefully	RB	B-ADVP	O
while	while	IN	B-SBAR	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Access	Access	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
left-sided	left-sided	JJ	I-NP	O
midline	midline	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
in	in	IN	B-PP	O
mid	mid	NN	B-NP	O
8/6	8/6	CD	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
removed	remove	VBN	I-VP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
one	one	CD	I-NP	O
week	week	NN	I-NP	O
and	and	CC	O	O
another	another	DT	B-NP	O
line	line	NN	I-NP	O
placed	place	VBN	B-VP	O
as	as	IN	B-SBAR	O
preferred	prefer	VBN	B-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
physician	physician	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
dialysis	dialysis	NN	I-NP	O
catheter	catheter	NN	I-NP	O
while	while	IN	B-SBAR	O
functional	functional	JJ	B-NP	O
does	do	VBZ	B-VP	O
seem	seem	VB	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
eroded	erode	VBN	I-VP	O
through	through	IN	B-PP	O
the	the	DT	B-NP	O
skin	skin	NN	I-NP	O
below	below	IN	B-PP	O
her	her	PRP$	B-NP	O
clavicle	clavicle	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
hemodialysis	hemodialysis	NN	I-NP	O
service	service	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
aware	aware	JJ	B-ADJP	O
and	and	CC	O	O
consider	consider	VB	B-VP	O
replacement	replacement	NN	B-NP	O
as	as	IN	B-SBAR	O
indicated	indicate	VBN	B-VP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
there	there	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
indication	indication	NN	I-NP	O
of	of	IN	B-PP	O
infection	infection	NN	B-NP	O
of	of	IN	B-PP	O
either	either	DT	B-NP	O
of	of	IN	B-PP	O
those	those	DT	B-NP	O
lines	line	NNS	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
at	at	IN	B-PP	O
high	high	JJ	B-NP	O
risk	risk	NN	I-NP	O
of	of	IN	B-PP	O
infection	infection	NN	B-NP	O
of	of	IN	B-PP	O
both	both	DT	B-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
hemodialysis	hemodialysis	NN	I-NP	O
as	as	IN	B-PP	O
per	per	IN	B-PP	O
the	the	DT	B-NP	O
Renal	Renal	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

Please	Please	VB	B-INTJ	O
feel	feel	VB	B-VP	O
free	free	JJ	B-ADJP	O
to	to	TO	B-VP	O
contact	contact	VB	I-VP	O
Dr.	Dr.	NNP	B-NP	O
Napoleon	Napoleon	NNP	I-NP	O
R	R	NNP	I-NP	O
Lafevre	Lafevre	NNP	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
ICU	ICU	NN	I-NP	O
physician	physician	NN	I-NP	O
here	here	RB	B-ADVP	O
at	at	IN	B-PP	O
Ciledall	Ciledall	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
with	with	IN	B-PP	O
any	any	DT	B-NP	O
questions	question	NNS	I-NP	O
you	you	PRP	B-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
dictation	dictation	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
three	three	CD	I-NP	O
to	to	TO	I-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Mcniel	Mcniel	NNP	I-NP	O
of	of	IN	B-PP	O
Vascular	Vascular	NNP	B-NP	O
Surgery	Surgery	NNP	I-NP	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
Plastic	Plastic	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Vitamin	Vitamin	NN	B-NP	O
C	C	NN	I-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
two	two	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Peridex	Peridex	NNP	B-NP	O
mouthwash	mouthwash	NN	I-NP	O
15	15	CD	B-NP	O
mL	mL	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Fluoxetine	Fluoxetine	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Heparin	Heparin	NN	B-NP	O
intravenous	intravenous	JJ	I-NP	O
1050	1050	CD	I-NP	O
units	unit	NNS	I-NP	O
per	per	IN	B-PP	O
hour	hour	NN	B-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
based	base	VBN	B-PP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
PTT	PTT	NN	I-NP	O
from	from	IN	B-PP	O
this	this	DT	B-NP	O
morning	morning	NN	I-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
yet	yet	RB	B-ADJP	O
available	available	JJ	I-ADJP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	B-protein
NPH	NPH	NN	I-NP	I-protein
35	35	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneous	subcutaneous	JJ	B-ADJP	O
every	every	DT	B-NP	O
morning	morning	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	B-protein
regular	regular	JJ	I-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
subcutaneous	subcutaneous	JJ	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

based	base	VBN	B-PP	O
on	on	IN	B-PP	O
fingersticks	fingerstick	NNS	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Atrovent	Atrovent	NNP	B-NP	O
inhaler	inhaler	IN	B-PP	O
8	8	CD	B-NP	O
puffs	puff	NNS	I-NP	O
by	by	IN	B-PP	O
ventilator	ventilator	NN	B-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Levoxyl	Levoxyl	NN	B-NP	O
88	88	CD	I-NP	O
mcg	mcg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Metoprolol	Metoprolol	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Dakin	Dakin	NNP	B-NP	O
's	's	POS	B-NP	O
solution	solution	NN	I-NP	O
one-quarter	one-quarter	NN	I-NP	O
strength	strength	NN	I-NP	O
topical	topical	JJ	B-ADJP	O
for	for	IN	B-PP	O
48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
two	two	CD	B-NP	O
times	time	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
resume	resume	VB	B-VP	O
wet-to-dry	wet-to-dry	JJ	B-NP	O
dressings	dressing	NNS	I-NP	O
as	as	IN	B-SBAR	O
dictated	dictate	VBN	B-VP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Ursodiol	Ursodiol	NN	B-NP	O
600	600	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
4	4	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
,	,	,	O	O
follow	follow	VBP	B-VP	O
INR	INR	NNP	B-NP	O
closely	closely	RB	B-ADVP	O
while	while	IN	B-SBAR	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Zinc	Zinc	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
220	220	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Simvastatin	Simvastatin	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Olanzapine	Olanzapine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Levofloxacin	Levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
48h	48h	NN	I-NP	O
.	.	.	O	O

through	through	IN	B-PP	O
the	the	DT	B-NP	O
date	date	NN	I-NP	O
specified	specify	VBN	B-VP	O
above	above	RB	B-ADVP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Nephrocaps	Nephrocaps	RB	B-NP	O
one	one	CD	I-NP	O
tab	tab	NN	I-NP	B-protein
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Miconazole	Miconazole	NN	B-NP	O
powder	powder	NN	I-NP	O
to	to	TO	B-PP	O
affected	affect	VBN	B-NP	O
areas	area	NNS	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Keppra	Keppra	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
daily	daily	JJ	I-NP	O
and	and	CC	O	O
250	250	CD	B-NP	O
mg	mg	NN	I-NP	O
supplemental	supplemental	JJ	I-NP	O
dose	dose	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
after	after	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Esomeprazole	Esomeprazole	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
G	G	NN	B-NP	O
tube	tube	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

21	21	CD	B-NP	O
.	.	.	O	O

Panafil	Panafil	NN	B-NP	O
spray	spray	NN	I-NP	O
topical	topical	JJ	B-VP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
to	to	TO	B-PP	O
heels	heel	NNS	B-NP	O
with	with	IN	B-PP	O
dressing	dress	VBG	B-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

22	22	CD	B-NP	O
.	.	.	O	O

Papain	Papain	NN	B-NP	O
and	and	CC	I-NP	O
urea	urea	NN	I-NP	O
topical	topical	JJ	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
to	to	TO	B-VP	O
only	only	RB	I-VP	O
be	be	VB	I-VP	O
used	use	VBN	I-VP	O
for	for	IN	B-PP	O
those	those	DT	B-NP	O
heels	heel	NNS	I-NP	O
if	if	IN	B-SBAR	O
Panafil	Panafil	NNP	B-NP	O
spray	spray	NN	I-NP	O
not	not	RB	B-ADJP	O
available	available	JJ	I-ADJP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
5-7387308	5-7387308	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Quentin	Quentin	NNP	B-NP	O
Orville	Orville	NNP	I-NP	O
Maki	Maki	NNP	I-NP	O
MD	MD	NNP	I-NP	O
Revero	Revero	NNP	I-NP	O
Angelesant	Angelesant	NNP	I-NP	O
Kanelan	Kanelan	NNP	I-NP	O
STREET	STREET	NNP	I-NP	O
,	,	,	O	O
HARLH	HARLH	NNP	B-NP	O
AND	AND	NNP	I-NP	O
HOSPITAL	HOSPITAL	NNP	I-NP	O
More	More	NNP	I-NP	O
Arv	Arv	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
SERAFIN	SERAFIN	NNP	B-NP	O
,	,	,	O	O
VERN	VERN	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
FABROS	FABROS	NNP	B-NP	O
,	,	,	O	O
HERIBERTO	HERIBERTO	NNP	B-NP	O
CLEMENTE	CLEMENTE	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
1283238	1283238	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
11/12/06	11/12/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
11/12/06	11/12/06	CD	B-NP	O

